KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.85

Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.

Theodoros Papathanasiou, Xi Chen, Fernando Carreno, Astrid McKeown, Sumita Roy-Ghanta, Lydia Eccersley, Ravi Kasinathan, Nashita Patel, Geraldine Ferron-Brady

Br J Cancer 135(1) 60-68

PMID41975042
PMCIDPMC13270149
DOI10.1038/s41416-026-03437-7
发表日期2026-04-13
入排依据:The record describes a pharmacokinetic-based exposure-response analysis for efficacy and safety, which is a secondary analysis. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required. Therefore, it is ineligible.
摘要

摘要

BACKGROUND: Belantamab mafodotin, bortezomib and dexamethasone (BVd) demonstrated clinical activity in the phase I/II DREAMM-6 (Arm B) study and significant clinical benefit in the phase III DREAMM-7 study for patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy. METHODS: Population pharmacokinetic-derived Cycle 1 (C1) belantamab mafodotin exposures were used to evaluate exposure-efficacy/exposure-safety relationships across multiple doses and schedules for benefit-risk assessment. RESULTS: Belantamab mafodotin C1 exposure was positively associated with response endpoints and grade ≥2/ ≥3 ophthalmic exam findings (OEFs), but not grade ≥2/ ≥3 ocular adverse events (oAEs) or best-corrected visual acuity (BCVA) worsening to 20/50 or worse in both eyes. Probability of very good partial response or better (≥VGPR) was higher than grade ≥3 oAEs/BCVA worsening in both eyes across C1 exposures; efficacy improved at higher C1 exposures without increased OEF risk. Model-based benefit-risk assessment showed a belantamab mafodotin starting dose of 1.9 mg/kg instead of 2.5 mg/kg would result in lower probability of ≥VGPR without reduction in BCVA worsening in both eyes/grade ≥3 oAEs. CONCLUSIONS: An initial belantamab mafodotin dose of 2.5 mg/kg for BVd yields deeper responses with minimal change in safety outcomes versus 1.9 mg/kg for patients with RRMM.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 1

Kaplan–Meier plots by belantamab mafodotin C avg quartiles (combined trials). PFS ( a ), TTR ( b ), DOR ( c ). ADC antibody-drug conjugate, C avg average concentration, DOR duration of response, PFS progression-free survival, TTR time to response, Q quartile.

A

Progression-free survival

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 4:short span
查看结果
B

Probability of response

Fig. 1 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 1 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Probability of ongoing response

Fig. 1 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Integrated E-R analyses (DREAMM-7). Belantamab mafodotin C avg relationship with probability of clinical response ( a ) and ocular safety overlaid with probability of ≥VGPR ( b ). ADC antibody-drug conjugate, AE adverse event, BCVA best-corrected visual acuity, C avg average concentration, ≥CR complete response or better, CTCAE Common Terminology Criteria for Adverse Events, KVA keratopathy and visual acuity, MRD minimal residual disease, ≥OR objective response or better, Q quartile, ≥VGPR very good partial response or better.
非 KM Figure